Risk of cancer is a major concern in the development of drugs for obesity and diabetes. In this fstudy, Brazilian researchers presenting at the annual meeting of the Endocrine Society in March, presented the results of a study that examined whether patients treated with GLP-1RAsad. a higher of breast neoplasms.
Sleep fragmentation and hypoestrogenism were shown to alter fasting nutrient utilization in this study, but not resting energy expenditure.
Hypothalamic obesity can be an acquired condition, either through a malfunctioning hypothalamus or as a result of treatment for a brain tumor.
Subclinical hypothyroidism is common patients over 70 years old, but how well older patients respond to treatment with levothyroxine (LT4) and liothyronine (LT3) is not well defined.
Proton pump inhibitors are FDA-approved for gastroesophageal reflux disease, gastric ulcers and other conditions, but not type 2 diabetes.
Study authors identified whether the hemoglobin A1c threshold level where reduction in bone turnover begins.
Study authors hypothesized that longer-acting testosterone replacement therapy will have significant impact on suppressing HPG axis compared with short-acting TRT preparations.
Study authors performed a retrospective review of a thyroid cancer cohort to evaluate the association between metabolic health and severity of thyroid cancer.
Study authors assessed the long-term effectiveness and safety of GH in real-life clinical practice and whether age mattered at the time of treatment initiation.
This study was launched to analyze the effect of setmelanotide, a melanocortin 4 receptor agonist, on weight loss and hunger reduction in patients with obesity and a confirmed diagnosis of Bardet-Biedl syndrome (BBS) or Alströmsyndrome (AS).
